Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-833923
administered alone, in combination with lenalidomide plus dexamethasone, or in combination
with bortezomib in subjects with relapsed or refractory multiple myeloma.